Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C65H81FN6O15 |
| Molecular Weight | 1205.3682 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(\C=N\N5CCC(CC5)N(C)C6(CC6)[C@@H]7CCN(C7)C8=C(C)C9=C(C=C(C(O)=O)C(=O)N9C=C8F)C%10CC%10)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C
InChI
InChIKey=OPZFMLLAJBIKAN-KYGXCNJYSA-N
InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(39-15-16-39)27-43(63(82)83)62(81)72(51)30-45(52)66/h12-14,20,26-28,30-31,33,35-36,39-41,46,53-54,58,74-78H,15-19,21-25,29H2,1-11H3,(H,68,80)(H,82,83)/b13-12+,26-20+,32-14-,67-28+/t31-,33+,35+,36+,40+,46-,53-,54+,58+,64-/m0/s1
| Molecular Formula | C65H81FN6O15 |
| Molecular Weight | 1205.3682 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:31:17 GMT 2023
by
admin
on
Sat Dec 16 11:31:17 GMT 2023
|
| Record UNII |
W2P7EF7O6O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
704419
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
12336
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
922717-97-3
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
W2P7EF7O6O
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
C190491
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
300000045598
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
145722022
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
In biochemical studies, CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Macromolecular biosynthesis studies confirmed that CBR-2092 has rifampin-like effects on RNA synthesis in rifampin-susceptible strains and quinolone-like effects on DNA synthesis in rifampin-resistant strains. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance. In contrast to quinolone comparator agents, no strains with altered susceptibility to CBR-2092 were found to exhibit changes consistent with altered efflux properties. The combined data indicate that CBR-2092 may have potential utility in monotherapy for the treatment of persistent S. aureus infections.
|
